- Incyte Pharmaceuticals has acquired Genome Systems, a USA-based genomics company. The acquisition enables Incyte to accelerate its gene sequence mapping program using Genome Systems' human DNA libraries and mapping capabilities. With 1995 sales of $2 million, Genome Systems will retain its name and become a wholly-owned subsidiary of Incyte, which is to issue 200,000 shares of common stock in the acquisition. Meanwhile, Incyte has announced a three-year mapping collaboration with Vysis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze